Protagonist Therapeutics (PTGX) Change in Receivables (2017 - 2024)

Protagonist Therapeutics has disclosed Change in Receivables across 8 years of filings, most recently posting $165.0 million for Q4 2024.

• Change in Receivables for Q4 2024 came in at $165.0 million, up 1550.0% year-over-year; the trailing twelve-month figure through Dec 2024 was $155.0 million (up 1451.55% YoY), and the FY2024 annual result was $155.0 million, up 1451.55% from the prior year.
• Change in Receivables came in at $165.0 million for Q4 2024 at Protagonist Therapeutics, up from -$43000.0 in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $290.0 million in Q1 2024 to a low of -$300.0 million in Q2 2024.
• The 5-year median for Change in Receivables is -$41000.0 (2023), against an average of $7.9 million.
• Peak annual rise in Change in Receivables reached 707321.95% in 2024, while the deepest fall reached 2499900.0% in 2024.
• Protagonist Therapeutics' Change in Receivables stood at -$363000.0 in 2020, then tumbled by 195.32% to -$1.1 million in 2021, then jumped by 89.27% to -$115000.0 in 2022, then jumped by 8795.65% to $10.0 million in 2023, then soared by 1550.0% to $165.0 million in 2024.
• The last three Change in Receivables figures came in at $165.0 million (Q4 2024), -$43000.0 (Q3 2024), and -$300.0 million (Q2 2024), per Business Quant data.